These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 15997385)

  • 41. Novel targeted therapies: the future of rheumatoid arthritis? Mavrilumab and tabalumab as examples.
    Combe B; van Vollenhoven R
    Ann Rheum Dis; 2013 Sep; 72(9):1433-5. PubMed ID: 23625979
    [No Abstract]   [Full Text] [Related]  

  • 42. Detecting and measuring disease modification in osteoarthritis. The need for standardized methodology.
    Dieppe P; Brandt KD; Lohmander S; Felson DT
    J Rheumatol; 1995 Feb; 22(2):201-3. PubMed ID: 7738938
    [No Abstract]   [Full Text] [Related]  

  • 43. [New treatments for rheumatoid arthritis].
    Girault V; Flipo RM
    Soins; 2004 Sep; (688):37-8. PubMed ID: 15515847
    [No Abstract]   [Full Text] [Related]  

  • 44. Impact of biological agents and tissue engineering approaches on the treatment of rheumatic diseases.
    da Silva MA; Martins A; Teixeira AA; Reis RL; Neves NM
    Tissue Eng Part B Rev; 2010 Jun; 16(3):331-9. PubMed ID: 20025434
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Review: basics of drug development in rheumatology.
    Mina-Osorio P
    Arthritis Rheumatol; 2015 Oct; 67(10):2581-90. PubMed ID: 26138901
    [No Abstract]   [Full Text] [Related]  

  • 46. Rheumatology in India--quo vadis?
    Handa R
    Nat Rev Rheumatol; 2015 Mar; 11(3):183-8. PubMed ID: 25366186
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rheumatology around the world: perspectives from Australia and New Zealand.
    McQueen FM
    Arthritis Res Ther; 2017 Feb; 19(1):24. PubMed ID: 28183342
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Progress and promise in rheumatology, measures of success. 19-21 March 2004 in Barcelona].
    Brandt J
    Z Rheumatol; 2004 Apr; 63(2):172-3. PubMed ID: 15112098
    [No Abstract]   [Full Text] [Related]  

  • 49. Advances in antibody engineering for rheumatic diseases.
    Schmid AS; Neri D
    Nat Rev Rheumatol; 2019 Apr; 15(4):197-207. PubMed ID: 30814691
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Experimental rheumatology--on the way to a fundamental understanding of rheumatic diseases].
    Radbruch A
    Z Rheumatol; 2005 Sep; 64(6):367-9. PubMed ID: 16184342
    [No Abstract]   [Full Text] [Related]  

  • 51. [A short history of anti-rheumatic therapy--VII. Biological agents].
    Pasero G; Marson P; Gatto B
    Reumatismo; 2011 Nov; 63(3):185-94. PubMed ID: 22257920
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Use of non-steroid anti-inflammatory agents in rheumatology].
    Sadowska-Wróblewska M
    Wiad Lek; 1984 Dec; 37(23):1891-9. PubMed ID: 6335798
    [No Abstract]   [Full Text] [Related]  

  • 53. The 2005 International Symposium on Advances in Targeted Therapies: what have we learned in the 2000s and where are we going?
    Maini RN
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4():iv106-8. PubMed ID: 16239377
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Orthopedic rheumatology].
    Holder M; Henniger M; Rehart S
    Z Orthop Unfall; 2013 Aug; 151(4):407-21; quiz 422-3. PubMed ID: 23963988
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Trends in treatment of rheumatic diseases].
    Burmester GR
    Z Rheumatol; 2003 Aug; 62(4):353-4. PubMed ID: 12928938
    [No Abstract]   [Full Text] [Related]  

  • 56. Use of prognostic markets to guide biologic therapies for rheumatoid arthritis.
    D'Arcy CA; Willkens RF
    J Rheumatol; 2002 Dec; 29(12):2662; author reply 2662-3. PubMed ID: 12465172
    [No Abstract]   [Full Text] [Related]  

  • 57. [New trends in rheumatology. The Danish Society of Rheumatology].
    Andersen LS; Gam AN; Hansen A; Kollerup G; Rasmussen C; Rasmussen JM; Schiøttz-Christensen B; Slot O; Thamsborg G
    Ugeskr Laeger; 2003 Mar; 165(12):1255. PubMed ID: 12701305
    [No Abstract]   [Full Text] [Related]  

  • 58. Recommendations for the use of biologic (TNF-alpha blocking) agents in the treatment of rheumatoid arthritis in Italy.
    Valesini G; Montecucco C; Cutolo M
    Clin Exp Rheumatol; 2006; 24(4):413-23. PubMed ID: 16956432
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases.
    Kvien TK; Heiberg ; Lie E; Kaufmann C; Mikkelsen K; Nordvåg BY; Rødevand E
    Clin Exp Rheumatol; 2005; 23(5 Suppl 39):S188-94. PubMed ID: 16273806
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Biosimilars].
    Burmester GR; Müller-Ladner U
    Z Rheumatol; 2015 Oct; 74(8):670-1. PubMed ID: 26450433
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.